Researchers have attempted to develop efficient antithrombogenic surfaces, and yet small-caliber artificial vascular grafts are still unavailable. Here, we demonstrate the excellent patency of tissue-engineered small-caliber long-bypass grafts measuring 20-30 cm in length and having a 2-mm inner diameter. The inner surface of an acellular ostrich carotid artery was modified with a novel heterobifunctional peptide composed of a collagen-binding region and the integrin α4β1 ligand, REDV. Six grafts were transplanted in the femoral-femoral artery crossover bypass method. Animals were observed for 20 days and received no anticoagulant medication. No thrombogenesis was observed on the luminal surface and five cases were patent. In contrast, all unmodified grafts became occluded, and severe thrombosis was observed. The vascular grafts reported here are the first successful demonstrations of short-term patency at clinically applicable sizes.

Some gel types have been reported to prevent left ventricular (LV) remodeling in myocardial infarction (MI) animal models. In this study, we tested biodegradable thermoresponsive gels. Poly(L-lactic acid)-poly(ethylene glycol) (PLLA-PEG) and poly(D-lactic acid)-poly(ethylene glycol) (PDLA-PEG) were synthesized by the polycondensation of Land D-lactic acids in the presence of PEG and succinic acid. Each of these block copolymers was used to prepare particles dispersed in an aqueous medium and mixed together to obtain a PLLA-PEG/PDLA-PEG suspension, which was found to show a sol-to-gel transition around the body temperature by the stereocomplex formation of enantiomeric PLLA and PDLA sequences. In the present study, the G 0 of the PLLA-PEG/PDLA-PEG suspension in the rheological measurement remained as low as 1 Pa at 20°C and increased 2 kPa at 37°C. The sol-gel systems of PLLA-PEG/PDLA-PEG might be applicable to gel therapy. The effect of the PLLA-PEG/PDLA-PEG gel injection was compared with that of a calciumcrosslinked alginate gel and saline in a rat MI model. The percent fractional shortening improved in the PLLA-PEG/ PDLA-PEG (20.8 ± 4.1%) and alginate gel (21.1 ± 4.8%) compared with the saline (14.2 ± 2.8%) with regard to the echocardiograph 4 weeks after the injection (p \ 0.05). There were reduced infarct sizes in both PLLA-PEG/PDLA-PEG gel and alginate gel compared with the saline injection (p \ 0.05). Moreover, a greater reduction in LV cavity area was observed with the PLLA-PEG/PDLA-PEG gel than with the alginate gel (p = 0.06). These results suggest that the PLLA-PEG/PDLA-PEG gel should have high therapeutic potential in gel therapy for LV remodeling after MI.

Abstract:The ability to control the micelle size of poly(lactic acid) and poly(ethylene glycol) (PLA-PEG) block copolymers is important for controlling their circulation in blood cell recognition, drug release and therapeutic effects. We successfully controlled the micelle size by changing the block number of copolymers (multiblock index). PLA-PEG multiblock copolymers with multiblock indexes ranging from 1.35 to 2.78 were synthesized by direct polycondensation with tin chloride/p-toluenesulfonic acid binary catalysts, using PEG with a molecular weight (Mw) of 3200 Da. The Mw of PLA-PEG copolymers increased with an increase in the multiblock index, while micelle size, measured by dynamic light scattering, decreased greatly from 349 to 28 nm. In addition, the X-ray diffraction peak of the PLA crystal disappeared when the multiblock index was increased. These results indicate that a multiblock structure is useful for controlling micelle size without changing the PLA/PEG composition or PEG molecular weight, which strongly influences other micelle features.